Chemed
The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict Chemed's revenues will grow 5.5% and EPS will grow 20.5%.
The average estimate for revenue is $360.2 million. On the bottom line, the average EPS estimate is $1.35.
Revenue details
Last quarter, Chemed reported revenue of $354.2 million. GAAP reported sales were 6.2% higher than the prior-year quarter's $333.4 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS details
Last quarter, non-GAAP EPS came in at $1.26. GAAP EPS of $1.10 for Q2 were 17% higher than the prior-year quarter's $0.94 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
Recent performance
For the preceding quarter, gross margin was 27.3%, 80 basis points worse than the prior-year quarter. Operating margin was 11.2%, 40 basis points better than the prior-year quarter. Net margin was 6.0%, 10 basis points worse than the prior-year quarter.
Looking ahead
The full year's average estimate for revenue is $1.44 billion. The average EPS estimate is $5.37.
Investor sentiment
The stock has a two-star rating (out of five) at Motley Fool CAPS, with 93 members out of 107 rating the stock outperform, and 14 members rating it underperform. Among 36 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 32 give Chemed a green thumbs-up, and four give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Chemed is outperform, with an average price target of $68.25.
- Add Chemed to My Watchlist.